Literature DB >> 24597104

Children's quality of life after adenotonsillectomy.

A Kanmaz1, T Muderris2, S Bercin2, M Kiris2.   

Abstract

OBJECTIVE: Although adenotonsillectomy is one of the most frequently performed surgical procedures in the pediatric population, its impact on health-related quality of life (HRQL) has not been well established. The objective of this study was to determine the impact of adenotonsillectomy on children's HRQL.
METHODS: Parents of the children who underwent adenotonsillectomy were invited to our clinic approximately one year after the surgery for a face-to-face survey to evaluate their child's HRQL. In total, 119 parents of children who underwent adenotonsillectomy for different reasons were interviewed. To quantify the benefit of the operation, the Glasgow Children's Benefit Inventory (GCBI) was used.
RESULTS: The mean GCBI score was 58 +/- 17.5 (minimum -22.9, maximum 79.2), indicating an increase in overall HRQL. Gender had no influence on the GCBI scores (p > 0.05). Satisfaction scores of the children aged 2-6 years were significantly higher than those of other age groups.
CONCLUSION: Surgical treatment of chronic adenotonsillar disease has a positive impact on children's HRQL. Although surgery is highly effective in all age groups, in terms of children's quality of life, better results can be obtained if the operation is done in the earliest years of life.

Entities:  

Mesh:

Year:  2013        PMID: 24597104

Source DB:  PubMed          Journal:  B-ENT        ISSN: 1781-782X            Impact factor:   0.082


  2 in total

1.  Is adenotonsillectomy safe in covid-19 era? Investigation of sars-cov2 in adenoid and tonsil tissues.

Authors:  Togay Muderris; Abdülhalim Aysel; Reyhan Yiş; Tuba Muderris; İbrahim Mehmet Ali Öktem; Onur Çorakçı
Journal:  Am J Otolaryngol       Date:  2022-04-07       Impact factor: 2.873

2.  Reliability of the Arabic Glasgow children's benefit inventory.

Authors:  Musaed A Alzahrani; Bshair A Aldriweesh; Mashael A Alharbi; Taghrid N Alrashidi
Journal:  Saudi Med J       Date:  2020-10       Impact factor: 1.484

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.